Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: major takeaways and highlights from the JP Morgan meeting; J&J bets on ADCs with Ambrx buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 January 2024, including: major takeaways and highlights from the J.P. Morgan meeting; Johnson & Johnson bets on ADCs with Ambrx Biopharma, Inc. buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J.P. Morgan 2024: Optimism With An Undercurrent Of Tension" - Scrip, 10 Jan, 2024.)
(Also see "J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout" - Scrip, 8 Jan, 2024.)
(Also see "J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology" - Scrip, 10 Jan, 2024.)
(Also see "Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming" - Scrip, 8 Jan, 2024.)
(Also see "Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership" - Scrip, 9 Jan, 2024.)